Li Jin-Ke, Wang Xiao-Xue, Fu Jia-Jun, Zhang Dan-Dan
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China.
Department of Health Management, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China.
World J Clin Oncol. 2024 Oct 24;15(10):1324-1332. doi: 10.5306/wjco.v15.i10.1324.
Cervical myeloid sarcoma (MS) is a rare hematological malignancy characterized by the formation of extramedullary soft tissue masses in the cervical region. Due to its uncommon presentation in the female reproductive system, cervical MS poses significant diagnostic and therapeutic challenges. Consequently, there is a pressing need for more research and clinical experience to better understand, diagnose, and manage this condition effectively.
This report details four cases, the diagnostic process, treatment strategy, and outcomes, discussing cervical MS as an initial clinical manifestation. The disease exhibits varied clinical presentations, such as irregular vaginal bleeding and palpation of cervical masses. The treatment approaches discussed include neoadjuvant chemotherapy, surgery, and postoperative chemotherapy, though managing the disease remains challenging. The report also features a comprehensive literature review that underscores the importance of immunohistochemistry for accurate diagnosis, identifying key markers, including myeloperoxidase, cluster of differentiation (CD) 68, and CD43, stressing the need for further research to improve treatment strategies and prognosis.
Immunohistochemical diagnosis and tailored therapeutic strategies are essential. Further research is crucial in improving outcomes and developing effective treatment protocols.
宫颈髓系肉瘤(MS)是一种罕见的血液系统恶性肿瘤,其特征是在颈部区域形成髓外软组织肿块。由于其在女性生殖系统中的罕见表现,宫颈MS带来了重大的诊断和治疗挑战。因此,迫切需要更多的研究和临床经验,以更好地理解、诊断和有效管理这种疾病。
本报告详细介绍了4例病例、诊断过程、治疗策略和结果,讨论了以宫颈MS作为初始临床表现的情况。该疾病表现出多种临床症状,如不规则阴道出血和宫颈肿块触诊。所讨论的治疗方法包括新辅助化疗、手术和术后化疗,尽管管理该疾病仍然具有挑战性。该报告还进行了全面的文献综述,强调了免疫组织化学对准确诊断的重要性,确定了关键标志物,包括髓过氧化物酶、分化簇(CD)68和CD43,强调需要进一步研究以改善治疗策略和预后。
免疫组织化学诊断和量身定制的治疗策略至关重要。进一步的研究对于改善治疗结果和制定有效的治疗方案至关重要。